Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead ...

Celebrating his company’s upsized initial public offering (IPO), Septerna CEO Jeffrey Finer ... On the same day last month, Bicara Therapeutics, MBX Bioscences and Zenas BioPharma went public ...

Septerna's GPCR-targeting platform could unlock ... s advanced platform accelerates the discovery of novel GPCR-targeting therapeutics, addressing a significant unmet need. Leveraging CryoEM ...

The deal is valued at up to $2.2bn, including more than $200m in upfront and near-term payments to Septerna. The partnership centres on the discovery and development of oral therapeutics aimed at ...

Dr. Kim joins Septerna from Design Therapeutics, where he served as Chief Medical Officer and led the clinical advancement of the company’s pipeline of small molecule genomic therapeutics.

Septerna's protracted initial public offering ... including recent Nasdaq debuts for MBX Biosciences, BioAge Labs, Bicara Therapeutics, Upstream Bio, and Zenas BioPharma.